SCHEMBL23218605

SCHEMBL23218605

COc1ccc(CC(=O)O)c(OCc2coc3ccc(-c4ccnc(CN)c4)cc23)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 1/20 0.41
MTNR1A P48039 6/20 0.39
NQO2 P16083 1/20 0.39
MTNR1B P49286 1/20 0.39
MAPT P10636 2/20 0.38
TSHR P16473 2/20 0.38
MAPK1 P28482 2/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
KDM4E B2RXH2 1/20 0.37
POLB P06746 2/20 0.37
THRB P10828 1/20 0.37
FFAR1 O14842 1/20 0.37
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592560 1.00 CFD (0.41) CFDMTNR1ANQO2MTNR1BMAPT
SCHEMBL23229167 0.90 MAPT (0.38) MTNR1ANQO2MTNR1BMAPTTSHR
SCHEMBL29591135 0.87 CFD (0.48) CFDPPARD
SCHEMBL23218316 0.87 CFD (0.48) CFDPPARD
SCHEMBL29591177 0.85 CFD (0.52) CFDMTNR1AMTNR1BFFAR1
SCHEMBL23218831 0.85 CFD (0.52) CFDMTNR1AMTNR1BFFAR1
SCHEMBL29591505 0.85 CFD (0.40) CFDMTNR1ANQO2MTNR1BMAPT
SCHEMBL23218484 0.85 CFD (0.40) CFDMTNR1ANQO2MTNR1BMAPT
SCHEMBL23218337 0.85 POLB (0.38) MTNR1ANQO2MTNR1BMAPTTSHR
SCHEMBL23218812 0.85 CFD (0.39) CFDKDM4EPOLBFFAR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885MTNR1A 3930/4885NQO2 2302/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885MTNR1A 3848/4885NQO2 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.